Bank of New York Mellon Corp Sells 1,693 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Bank of New York Mellon Corp trimmed its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 0.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 399,424 shares of the biotechnology company’s stock after selling 1,693 shares during the quarter. Bank of New York Mellon Corp owned about 0.89% of United Therapeutics worth $140,933,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of the business. Wealth Enhancement Advisory Services LLC increased its stake in shares of United Therapeutics by 0.8% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 4,913 shares of the biotechnology company’s stock worth $1,761,000 after acquiring an additional 39 shares in the last quarter. MBM Wealth Consultants LLC grew its position in United Therapeutics by 1.9% during the 4th quarter. MBM Wealth Consultants LLC now owns 2,151 shares of the biotechnology company’s stock valued at $775,000 after purchasing an additional 41 shares during the last quarter. UMB Bank n.a. grew its position in United Therapeutics by 4.9% during the 4th quarter. UMB Bank n.a. now owns 1,101 shares of the biotechnology company’s stock valued at $388,000 after purchasing an additional 51 shares during the last quarter. Access Investment Management LLC grew its position in United Therapeutics by 0.8% during the 4th quarter. Access Investment Management LLC now owns 7,335 shares of the biotechnology company’s stock valued at $2,588,000 after purchasing an additional 55 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB grew its position in United Therapeutics by 31.9% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 58 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director Louis W. Sullivan sold 26,209 shares of United Therapeutics stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the sale, the director now owns 5,051 shares in the company, valued at $1,885,134.22. This trade represents a 83.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $361.95, for a total transaction of $3,619,500.00. Following the sale, the chief operating officer now owns 2,577 shares in the company, valued at approximately $932,745.15. The trade was a 79.51 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 124,164 shares of company stock worth $45,278,893 over the last quarter. Insiders own 11.90% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on UTHR. The Goldman Sachs Group increased their price objective on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research report on Friday, November 1st. UBS Group increased their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. StockNews.com downgraded shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday. Finally, HC Wainwright reissued a “buy” rating and set a $425.00 price objective on shares of United Therapeutics in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $388.25.

United Therapeutics Trading Down 1.1 %

NASDAQ UTHR opened at $319.96 on Friday. United Therapeutics Co. has a 12 month low of $221.53 and a 12 month high of $417.82. The stock has a market cap of $14.28 billion, a price-to-earnings ratio of 14.05, a PEG ratio of 0.97 and a beta of 0.57. The company’s 50 day moving average is $359.65 and its two-hundred day moving average is $360.46.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping analysts’ consensus estimates of $6.10 by $0.09. The company had revenue of $735.90 million for the quarter, compared to analysts’ expectations of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same quarter last year, the business earned $4.36 EPS. Sell-side analysts forecast that United Therapeutics Co. will post 24.48 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.